Gary Veron

Hogan Lovells

+ Follow Contact

Latest Posts › Biosimilars

Share:

FTC continues to focus on competition in pharmaceutical markets, supports FDA guidance on biosimilars

On August 20, 2024, the Federal Trade Commission (FTC) filed a comment letter in support of the Food and Drug Administration’s (FDA’s) June 2024 draft guidance on biosimilar interchangeability (the “Draft Guidance”). When...more

8/30/2024 / Biologics , Biosimilars , Federal Trade Commission (FTC) , Food and Drug Administration (FDA) , Intellectual Property Protection , Patents , Pharmaceutical Industry , Pharmaceutical Patents

Four new FDA guidances and proposed rule advance biosimilars policy framework

Yesterday, FDA released a series of guidances that aim to advance the agency’s biosimilars policy framework, along with a proposed rule on the definition of a “biological product,” which incorporates changes made by the...more

12/12/2018 / Biologics Price Competition and Innovation Act of 2009 , Biosimilars , Food and Drug Administration (FDA) , Healthcare , Life Sciences , New Guidance , Proposed Rules , Regulatory Agenda , Research and Development , Rulemaking Process

FDA launches Biosimilars Action Plan to spur biologics competition, finalizes labeling guidance

On July 18, FDA Commissioner Scott Gottlieb, M.D., announced the release of FDA’s Biosimilars Action Plan (BAP), saying it would help enable a path to competition for biologics from biosimilars, while preserving incentives...more

8/10/2018 / Biologics , Biosimilars , Competition , Food and Drug Administration (FDA) , Hatch-Waxman , Pharmaceutical Industry , Prescription Drugs , Product Labels , Regulatory Oversight , Regulatory Requirements

3 Results

View per page

Page: of 1